Who is sponsoring NCT00978107?

NCT00978107 is sponsored by Transgene.

What condition does NCT00978107 study?

NCT00978107 studies Hepatocellular Carcinoma.

What drugs are being tested in NCT00978107?

Interventions: MVA-FCU1, flucytosine.

What is the status of NCT00978107?

NCT00978107 is currently COMPLETED.

Last reviewed 2014-07-15 · How we verify

A Phase I, Open-label, Dose-escalating Study of the Safety or Percutaneous Intra-tumoral Injection of TG4023 (MVA-FCU1) Combined With Systemic Administration of 5-fluorocytosine in Patients With Primary or Secondary Hepatic Tumors.

NCT00978107 Phase 1 COMPLETED

This trial is a phase I, open-label, dose-escalating study of the safety or percutaneous intra-tumoral injection of TG4023 (MVA-FCU1) combined with systemic administration of 5-fluorocytosine in patients with primary or secondary hepatic tumors.

Details

Lead sponsor	Transgene
Phase	Phase 1
Status	COMPLETED
Enrolment	16
Start date	2009-09
Completion	2011-09

Conditions

Hepatocellular Carcinoma

Interventions

MVA-FCU1, flucytosine

Primary outcomes

Maximal tolerated dose — 6 months

Countries

France